Skip to main content
. 2021 Jan 28;60(10):4568–4580. doi: 10.1093/rheumatology/keab047

Fig. 1.

Fig. 1

Patient disposition in the trial of (A) patients with sJIA and (B) patients with pJIA

Withdrawal by patient: TCZ-naive, n = 1. Withdrawal because of lack of efficacy: TCZ-naive, n = 4; TCZ-prior, n = 1. BW: body weight; Q10D: every 10 days; QW: every week; Q2W: every 2 weeks; TCZ: tocilizumab; pJIA: polyarticular JIA; sJIA: systemic JIA.